Intersect ENT — Investor Presentation (January 2019)
24 slides from Intersect ENT's investor presentation, Jan 7, 2019
Slide 1: Delivering Innovation. Where It's Needed.
Delivering Innovation. Where It’s Needed. January 2019 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange Act”), including, without limitation, statements
Slide 3: Intersect ENT Opportunity
Intersect ENT Opportunity LARGE MARKET $3B+ TAM in US for Chronic Sinusitis GROWTH DRIVERS Expanded Salesforce PRODUCT PIPELINE Enrolling ASCENDTM RCT for Drug-Coated Sinus Balloon FINANCIAL STRENGTH GM 79% (Q318) Cash Balance $104M (Q318**) REVENUE ($M) * Preliminary estimate based on currently ava
Slide 4: Dedicated to Transforming ENT Care in Adults
Dedicated to Transforming ENT Care 1 in 8 Adults Top 10 Most Costly Condition for US Employers 25 work days lost per year per patient Focus on Chronic Sinusitis Providing innovative, clinically meaningful therapies
Slide 5: PROPEL & SINUVA: Innovative & Clinically Proven
PROPEL & SINUVA: Innovative & Clinically Proven 1ST DRUG RELEASING IMPLANTS FOR CHRONIC SINUSITIS Local Delivery, Mechanical Spacing, Bioabsorbable Improving Surgical Outcomes Managing Recurrent Disease FAMILY
Slide 6: Portfolio Extending Across Chronic Sinusitis Indications and Care Settings
OFFICE HOSPITAL / ASC Portfolio Extending Across Chronic Sinusitis Indications and Care Settings Frontal Maxillary Ethmoid
Slide 7: Large Patient Population and Market
Large Patient Population and Market * Company estimates. ~2M Patients, $3B TAM Early Stage (Office) Advanced (Surgery) Continuing (Office) PATIENTS 800,000 540,000 635,000 TAM $1.1B $0.8B $1.3B Addressing CS Across the Continuum of Care
Slide 8: Commitment to Evidence-Based Innovation
Commitment to Evidence-Based Innovation 14 Prospective Clinical Studies 40 Centers in US > 900 Patients Pilot (PROPEL) 43 Patients 4 Sites ADVANCE 50 Patients 7 Sites ADVANCE II 105 Patients 11 Sites PROGRESS (mini) 80 Patients 11 Sites PROGRESS (Contour) 80 Patients 12 Sites EXCEED (Contour) 15 Pat
Slide 9: PROPEL Family: Improving Surgical Outcomes
FAMILY Improving Surgical Outcomes
Slide 10: PROPEL Family Surgical Products to Improve Outcomes
PROPEL Family 3 Surgical Products to Improve Outcomes Advanced into Surgically Enlarged Sinus Cavity OPENS Self-Expanding Implant Conforms to and Holds Open Sinus DELIVERS Sustained, Targeted Delivery of Steroid Over 30 Days MAINTAINS Opening by Reducing Post-Operative Inflammation and Scarring MULT
Slide 11: PROPEL and PROPEL Mini Clinically Proven Outcomes
Approved for Placement in Ethmoid Sinus Only Device Used in Sinus Surgery Backed by Level 1a Evidence 35% Reduction in Post-Operative Intervention PROPEL and PROPEL Mini Clinically Proven Outcomes Meta-analysis: Han JK, Marple BF, Smith TL et al. Int Forum Allergy Rhinol, Vol. 2, No. 4, July/August
Slide 12: PROPEL Contour Clinically Proven Outcomes
p=0.1094 FRONTAL AND MAXILLARY SINUSES p=0.0023 P<0.0001 p=0.0078 PROPEL Contour Clinically Proven Outcomes CONTOUR STUDY 80 Patient Prospective, Randomized, Blinded, Multi-Center Trial Post-operative Intervention* Oral Steroid Intervention** Occlusion/ Restenosis** 65% 35% 63% Surgical Intervention
Slide 13: Growth Drivers and Continuing Commercial Traction
GROWTH DRIVERS Leverage expanded salesforce (~140 reps) Continue PROPEL Contour Roll-out Add New Accounts Expand Physician Usage PROPEL FAMILY Continuing Commercial Traction 1 in 8 Sinus Surgeries ~ 50% of Accounts TODAY 1 in 3 ENTs ~ 280,000 Patients Treated As of Q4, 2018
Slide 14: Focus on Higher Quality of Care with Lower Overall Cost
Focus on Higher Quality of Care with Lower Overall Cost COST EFFECTIVENESS STUDY1 Placement of PROPEL following FESS “is a cost-effective intervention for preventing a postoperative intervention within 60 days after surgery.” BUDGET IMPACT MODEL2 Use of PROPEL is “expected to save the plan money” Re
Slide 15: SINUVA (mometasone furoate) sinus implant
(mometasone furoate) snus implant Designed to
Slide 16: Designed for Patients Who Have Had Prior Surgery
Designed for Patients Who Have Had Prior Surgery Dilates Obstructed Cavity Delivers~4x Steroid (vs. PROPEL) Over 90 Days 100% Patient Compliance OVERVIEW ETHMOID SINUS SINUVA Office Treatment for Recurrent CRS/Polyps Ethmoid Sinus Pre-implant Immediately Post-implant 6 Weeks Post-implant
Slide 17: SINUVA Clinically Proven Outcomes
NDA Approved December 2017 4 Studies Conducted in over 400 patients Targeted Commercial Launch Q218 SINUVA Clinically Proven Outcomes ETHMOID SINUS 300 Patient Prospective, Randomized, Blinded, Multi-Center Trial CO-PRIMARY and KEY SECONDARY ENDPOINTS MET Reduction in Bilateral Polyp Grade (p=0.0073
Slide 18: SINUVA Reduction in Polyps and Sinus Obstruction
SINUVA Reduction in Polyps and Sinus Obstruction ENDOSCOPIC OUTCOMES * p-value < 0.0001 BILATERAL POLYP GRADE ETHMOID SINUS OBSTRUCTION Treatment Control Change from Baseline 0% -5% -10% -15% -20% -25% -30% Data on file, Intersect ENT. RESOLVE II CR-00014 Rev. 1.0 January 2018. Grading by Clinical I
Slide 19: SINUVA Reimbursement Basics
SINUVA Reimbursement Basics *Ernst FR, Imhoff RJ, DeConde, Manes RP. Steroid-Eluting Sinus Implant Versus Revision Surgery for Patients with Recurrent Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): An Economic model. Poster presentation at 2018 International Society of Pharmacoeconomics and Outc
Slide 20: SINUVA Foundation Established in 2018
SINUVA Foundation Established in 2018 Positive Clinical Experience ~1200 Patients Treated ~500 Physicians Top 6 Commercial Payors Providing Access Established Network of SPs & SDs Prior-Authorizations in <30 Days Increasing Use of Buy and Bill ~25% Salesforce Growth in ‘18 Expanded Reimbursement Tea
Slide 21: ASCEND Drug Coated Balloon
ASCEND Drug Coated Balloon Emerging Pipeline Product Conducting Clinical Study of Investigational ASCEND Mometasone Furoate Drug Coated Balloon (DCB) Designed to Improve Peripheral Sinus Patency Regulatory Path: PMA MARKET OPPORTUNITY Focus primarily on office setting of care Expands product offerin
Slide 22: Emerging Opportunity Outside the US
Emerging Opportunity Outside the US ~540K FESS / Year ~450K FESS / Year ~250K FESS / Year OUS TO CONTRIBUTE TO LONG-TERM GROWTH Establishing Germany as European beachhead Expanding to Switzerland, Austria and England Pursuing Japan Shonin Regulatory Approval
Slide 23: 2019 Outlook
REVENUE ($M) 2019 Outlook COMMERCIAL Leverage 2018 Salesforce Expansion Ramp SINUVA REIMBURSE-MENT Streamline Product Access Secure Product Specific J Code to Support SINUVA Long-term * Preliminary estimate based on currently available information. Has not been audited or reviewed by our independent
Slide 24: Intersect ENT: Delivering Innovation. Where It's Needed.
® % intersect ENT DELIVERING INNOVATION. WHERE IT’S NEEDED.